Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KRAS G12V
i
Other names:
KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Related tests:
therascreen® KRAS RGQ PCR Kit (5)
therascreen® KRAS RGQ PCR Kit (5)
Associations
(36)
News
Trials
Search handles
@ADesaiMD
@AndresFCardonaZ
@BenWestphalen
@StephenVLiu
@ogarrieta
@pashtoonkasi
@weldeiry
Search handles
@ADesaiMD
@AndresFCardonaZ
@BenWestphalen
@StephenVLiu
@ogarrieta
@pashtoonkasi
@weldeiry
Filter by
Latest
8ms
Impact of KRAS G12D and concurrent mutations on NSCLC outcomes. Our cohort shows 15.6% mKRAS (32, 32, 14% for G12C, G12D and G12V), G12D is associated with female and a lower smoking rate (pack/year). @incanMX @AndresFCardonaZ @Ecaballep https://t.co/YVgxHYVNAZ (@ogarrieta)
8 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12
10ms
#ASCO23 Abs9100 #LCSM by @Joshua_Reuss 🔬 RAMP 202, a phase 2 trial, evaluated the efficacy and safety of avutometinib ± defactinib in previously-treated KRASG12V mt NSCLC. 📊 Of 35 pts with KRAS G12V, 16 received monotherapy, and 19 received combination therapy. ➡️In the… https://t.co/A3N7rq0Epc (@ADesaiMD)
10 months ago
Clinical • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12V • KRAS G12
|
avutometinib (VS-6766) • defactinib (VS-6063)
1year
A 12-11 One more trial!! Pan #RAS G12i Ph I/Ib 📌https://t.co/xNGnaEYbli 📌n=141 📌RMC6326 📌For KRAS G12A/G12D/ G12R/ G12S or G12V mutant #CRC & other solid tumors 📌Primary end points: DLT, Safety 📌Trial open in the US https://t.co/2y2vpJDmAH #CRCTrialsChat #CRCSM (@manjuggm)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
|
KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S
1year
A 12-13 🇺🇸#NCI #KRAS G12V adoptive cell trial phase I/II 📌https://t.co/f6PUwQVJao 📌n=110 📌Peripheral🩸Leukocytes transduced with anti-KRAS G12V mTCR in HLA-A*11:01 (+) pts with St IV G12V mutant RAS solid tumors 📌Primary end points: Clinical response, safety #CRCTrialsChat (@manjuggm)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
|
KRAS G12V • RAS mutation • KRAS G12
1year
Clinical trials of TCR engineered autologous T cells targeting HLA-restricted KRAS neoepitopes (including G12D & G12V) are now ongoing in patients with #PancreaticCancer & other solid cancers. Two examples below: https://t.co/Wty1VFhFzx https://t.co/4y425IGNyH (Specific to G12V). (@Aiims1742)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12
over1year
Data presented by @tajiknia #AACRJCA22 shows MRTX1133 suppression of pERK at nM doses & synergies with 5-FU in CRC & pancreatic cancer cells with #KRAS G12D, G12V, & G13D. More studies needed before excluding non-G12D mutations from trials @BrownUCancer @BrownMedicine #eldeirylab https://t.co/DUlynIqYZH (@weldeiry)
over 1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12 • KRAS G13
|
5-fluorouracil • MRTX1133
almost2years
Not targetable, finding more #KRAS G12V doesn't matter?! #FRAME study by @udai_banerji identified strong signal in #KRAS #NSCLC 🫁 G12V, with initial 57% RR, 100% DCR. Ongoing #RAMP202 study, NCT04620330, lead by dr. Ross Camidge also expanded with #BRAFm @CUCancerCenter (@CrozrX)
almost 2 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12V • KRAS G12
almost2years
More to the RAS Story: Moving Beyond KRAS G12C Mutations in Lung Cancer talk by Colin R. Lindsay, #ASCO22 @OncoAlert KRASG12Di RMC-9805 binds to KRASG12D active form KRAS G12Vi RMC-also targets active form New way of targeting using cyclophilinA as a chaperone (@manjuggm)
almost 2 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12
|
RMC-9805
almost2years
This paragraph is like, copy-pasted from a few years ago! Borderline malicious with the information for professionals and patients with #KRAS #NSCLC G12V, 2nd most prevalent 🫁 KRASm. Vertical downstream blockade can be efficacious, safe, durable, comprehensive +expanding ▶️#BRAF (@CrozrX)
almost 2 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
KRAS G12V • KRAS G12
2years
I'm hoping #RAMP202 #KRAS G12V #NSCLC study by Dr. Ross Camidge @CUCancerCenter, readout in 2H 2022 may confirm early strong signal identified in #FRAME study and hopefully show us all of the patients still alive and at least half responding, 100 DCR! Exciting g12C #, room for 📈 (@CrozrX)
2 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12V • KRAS G12
2years
"Preclinically, VS-6766 and EGFR inhibition showed synergy in KRAS mt CRC cell lines, including cell lines harboring KRAS G12D and G12V mts, and CRC PDX of KRAS G12V mt CRC showed tumor regression with this combination." #KRAS #CRCSM #GI22 @KRASKickers (@fireflyann)
2 years ago
Preclinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12
|
avutometinib (VS-6766)
2years
Many #NSCLC patients with a #KRAS mutation are still in need of targeted treatments. @AlexSpiraMDPhD of @VCSpecialists, talks the #RAMP202 study investigating VS-6766 alone and with defactinib, now enrolling #NSCLC patients with a #KRAS mutation with a focus on #G12V. #LCSM (@VerastemOncolog)
2 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12V • KRAS G12
|
avutometinib (VS-6766) • defactinib (VS-6063)
over2years
Targeting KRAS mutant lung cancer: light at the end of the tunnel. Interesting, another @BarbaDelCid collaboration inhibiting cRAF #RAF1 shows early strong signal in #KRAS G12V #NSCLC (RAMP202), @udai_banerji (FRAME) with 57% RR. #cRAF #MEK #SOS #SHP2 #FAK #Pi3K #mTOR https://t.co/PIYgsqVW9r (@CrozrX)
over 2 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12V
over2years
Up to five million dollars will be provided for an early phase #ClinicalTrial in #PancreaticCancer Priority areas: - KRAS G12D/ G12V inhibitors - Downstream effectors of Ras - Metabolic vulnerabilities LOI is due Jan 24, 2022. (@Aiims1742)
over 2 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V
over2years
#RAMP202 #KRAS G12V #NSCLC clinical study has landed in #Europe #Spain!! (@CrozrX)
over 2 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12V • KRAS G12
over2years
Phenomenal results! AEs are creeping up a little. But, efficacy DOR, PFS are outstanding! Congrats @udai_banerji @royalmarsdenNHS @ICR_London @ICR_DDU_IIT #OvarianCancer #LGSOC #KRAS Let's see where G12V #NSCLC with early signal of 57% RR takes us! https://t.co/Jxwn96Qc5q (@CrozrX)
over 2 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12V • KRAS G12
over2years
#ESMO21 Distribution as expected, KRAS G12C most common followed by G12V. Most had not received 1L IO therapy reflecting the accrual period of the study. #LCSM @myESMO (@StephenVLiu)
over 2 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12V • KRAS G12
over2years
Link; https://t.co/EVIdQzNHMp So, while G12C found its match through direct #KRAS inhibition, key driver of KRAS-G12V mutant #NSCLC is through CRAF. Early signal 57% RR. And what's beautiful is #synergistic action across KRAS variants. (@CrozrX)
over 2 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12V
over2years
Congrats!! Also congrats @udai_banerji @royalmarsdenNHS @CR_UK on their work on #KRAS #NSCLC #lungcancer, G12V variant in particular! (@CrozrX)
over 2 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12V • KRAS G12
over2years
Next update is @myESMO #ESMO21 So far, strong signal identified in #NSCLC #KRAS G12V with 57% RR @AACR, LGSOC #KRAS 70% RR Hopefully, one of the #KRAS backbone options to come. Response across multiple variants of KRAS. https://t.co/vUNkZj9G6m (@CrozrX)
over 2 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12V • KRAS G12
over2years
KRAS G12V #NSCLC study is recruiting in #USA, hopefully this platform becomes available in #EU soon! Tolerable, 57% RR. #RAMP202 #CRAF #RAF #MEK https://t.co/jIocLPjk8x VS-6766 recent publication, interesting PDL1 results not just NSCLC, but TNBC, also! https://t.co/inrp1RjhOt (@CrozrX)
over 2 years ago
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)
|
KRAS G12V • KRAS G12
|
avutometinib (VS-6766)
over2years
From the modest activity as monotherapy ▶️ strong signal in #KRAS #G12V #NSCLC ▶️ a potential triplet KRAS #cancer killer combo across multiple variants, cancers?! #FAKi archetype #FocalAdhesionKinase #PYK2 #HIPpO #YAP #TAZ #Sotorasib #Defactinib #VS6766 #Adagrasib #g12C #g12D (@CrozrX)
over 2 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12
|
Lumakras (sotorasib) • Krazati (adagrasib) • avutometinib (VS-6766) • defactinib (VS-6063)
almost3years
Wanted to ask either of you @JacobPlieth @bradloncar about $VSTM's continuing development of 6766 in combo with defactinib. Specifically regarding updated toxicity profile and the rationale for targeting G12V in KRAS NSCLC. (@ClerkiusM)
almost 3 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12V • KRAS G12
|
defactinib (VS-6063)
almost3years
Officially “undruggable” no more. There’s now an approved KRAS inhibitor for G12C mutant #LungCancer - amazing to see this progress for patients happen in a relatively short time. Next up - G12D, G12V & combos. Keep believing & investing in science! https://t.co/sLejBnR432 (@Aiims1742)
almost 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12
almost3years
Add mutant KRAS G12V to the actionable repertoire. A monobody (and its “PROTAC-like” derivative) for selective inhibition of KRAS G12C & G12V mutants in #PancreaticCancer. From @nyulangone researchers https://t.co/rmHdfPAbHs (@Aiims1742)
almost 3 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12V
almost3years
#MAPK RAF /MEKi Vs-6766 (RO5126766) with 70% RR in #KRASm #LGSOC, responses across multiple variants and #WT #ovariancancer and 57% RR in #KRAS G12V #NSCLC #RAMP202 #RAMP201 #clinicaltrial Efficacy, DOR, safety profile ✔✅ ✔✅ (@CrozrX)
almost 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12V • KRAS G12
|
avutometinib (VS-6766)
almost3years
🙌🏾 to open at @IntMedatIowa few days. While #pancreascancer #PANCSM is the major cohort, the vaccine 💉 is for multiple KRAS mutations. So #lcsm #HPBCSM #cholangiocarcinoma #CRCSM and I believe #ovariancancer. Using the #ctDNA @NateraOncology. G12D G12R G12V G12A G12C G12S G13D (@pashtoonkasi)
almost 3 years ago
Circulating tumor DNA
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12S
almost3years
Very interesting. To your knowledge, are these the first documented responses in G12V KRAS mt NSCLC in the relapsed setting? (@cancer_end)
almost 3 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12V • KRAS G12
3years
Twice the excitement & #patients #KRAS 🎯G12C 🎯G12V #PrecisionMedicine #LCSM #ELCC21 (@kRasKickers)
3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12V • KRAS G12
3years
#KRAS #lungcancer variants G12V G12D G12A WT @IASLC @LungCancerEu @GO2Foundation @ALKLungCancer @lcrf_org @LUNGevity Dr. Ross Camidge discusses launch of #RAMP202 Vs-6766 /Defactinib registrational clinical study (RAF/MEKi -FAKi) @dave6408 @SarahCannonDocs https://t.co/U33fPMonYL (@CrozrX)
3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
|
avutometinib (VS-6766) • defactinib (VS-6063)
over3years
I'll dare to put in little diversity in here! ☺#wizard @udai_banerji accomplishment in a fantastic RAF •MEKi efficacy, DOR and safety profile in KRAS •G12V •G12D •G12A •WT variants! Amazing breakthrough in #LGSOC #NSCLC #PancreaticCancer #CRC #LessIsMore #IntermittentDosing (@CrozrX)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
over3years
FAKi Defactinib /HDAC Vorinostat could potentially change #Glioblastoma #BrainTumor #cancer treatment. 🔺1st thread post🔺 Also, interesting #KRAS G12V slides @udai_banerji @CR_UK @royalmarsdenNHS (@CrozrX)
over 3 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12V • KRAS G12
|
Zolinza (vorinostat) • defactinib (VS-6063)
over3years
This is just crazy awesome. #CTCs 🔴🟣🔵not only in metastatic GI cancers are we able to enumerate & stain, but single cell analysis shows as in this example a KRAS-G12V & a PIK3CA mutation in a #pancreascancer patient. #PANCSM where tissue is often insufficient for analysis. 💡 (@pashtoonkasi)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
PIK3CA mutation • KRAS G12V • KRAS G12
over3years
Promising multiple KRAS variants platform in dual RAF •MEK inhibitor VS-6766 (RO5126766) FAKi •Defactinib. G12V G12D G12A WT, giant leap in KRAS development! Efficacy, durability, safety profile! @udai_banerji is a wizard! @JackWestMD #NSCLC #PDAC #CRC #LGSOC (@CrozrX)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
|
avutometinib (VS-6766) • defactinib (VS-6063)
over3years
I'll just add phenomenal efficacy and safety profile ▶ #NSCLC G12V G12D WT KRAS variants breakthrough by @udai_banerji and on the cancer COVID19 topic the very same repurposed drug promising potential. Vs-6766 (RO5126766) (@CrozrX)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12
|
avutometinib (VS-6766)
over3years
Not just G12C, but G12V •G12D •WT •G12A KRAS variants #NSCLC #LGSOC #PancreaticCancer #PDAC #CRC Vs-6766 /Defactinib https://t.co/KpdKLDWdLq (@CrozrX)
over 3 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
|
avutometinib (VS-6766) • defactinib (VS-6063)
over3years
It's not only G12C with KRAS breakthrough data, but also G12D G12V G12A WT.. which bears major implications for pancreatic cancer, CRC, MM.. Also, synergistic combo with AMG510 in KRAS G12C. Phenomenal 65% ORR, 4% TEAE! Expanding cohorts.. https://t.co/VDN8PpGNsm (@CrozrX)
over 3 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
|
Lumakras (sotorasib)
over3years
65% ORR, 4% TEAE across G12D G12V WT G12A.. KRAS variants. LGSOC cohort expansion to pancreatic cancer, CRC, NSCLC. Also great synergy with AMG510 KRAS G12C. https://t.co/VDN8PpYoQW (@CrozrX)
over 3 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
|
Lumakras (sotorasib)
over3years
Did you assess allelic status of the PALB2 mt? At #ESMO20 we reported that alterations in core HRD genes only lead to functional consequences (gLOH high) if biallelic. Also, KRas G12V argues for classic #pancsm & MSH6 variant while TMB low against MSI. Response to platinum? (@BenWestphalen)
over 3 years ago
KRAS (KRAS proto-oncogene GTPase) • PALB2 (Partner and localizer of BRCA2) • MSH6 (MutS homolog 6)
|
KRAS G12V • TMB-L • KRAS G12
over3years
Here's an idea, KRAS G12D, G12V, G12C swarm clinical study based on this data. Outstanding response result and safety profile done by @udai_banerji (1) #PDAC #CRC #NSCLC 3rd pic is a map of relative breakdown of RAS variants corresponding to this breakthrough clinical study (@CrozrX)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12
over3years
Is #KRAS code cracked? Not only phenomenal response rate 56% (2 additional responses after data cutoff = 65%) , but safety profile, also! 4% TEAE with MEKs! #wizard @udai_banerji #cancer #research G12V G12D G12C #breakthrough strategy #development #LGSOC #PDAC #CRC #NSCLC (@CrozrX)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12V
over3years
I suggest reviewing LAD NSCLC patients included in the PROSPECT dataset, especially those KRAS-G12V+LKB1 to verify the response to Durva (@AndresFCardonaZ)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12V • KRAS G12
|
Imfinzi (durvalumab)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login